Amgen (AMGN), UCB Present Data from Romosozumab Phase 2 in Postmenopausal Women with Low BMD
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) and UCB announced results from several exploratory analyses of the Phase 2 study evaluating romosozumab in postmenopausal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
